Kevin Kunzmann

A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.

Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.

New AAO 2022 data show the novel treatment administration may eventually save patients money versus standard anti-VEGF injfections.

New findings show the investigative single-dose agent is safe and associated with reduced rescue-dose anti-VEGF treatment.

Comparison of 12- and 24-month regimens of common nAMD treatment show little difference in the common adverse event in patient eyes.

Simon Walsh, MD, and Elizabeth Estes join Lungcast to discuss advancements in biomarker and treatment option deliberation for the rare disease through data.

New EADV data suggest clinicians may need to uniquely treat patients with adult-onset eczema based on inflammatory pathways.

The approval is based on data from 2 clinical trials showing the agent improved the rate of post-operation patients avoiding sickness by 50%.

The novel OX40 inhibitor molecule showed significant benefit for patients in new EADV 2022 data. A lead author discusses its potential.

The daily TYK2 inhibitor agent was associated with improved rates of psoriasis surface improvement versus apremilast in clinical trials.

The Icahn investigator discusses her team's new EADV 2022 data on the JAK inhibitor.

In this podcast episode, Jorge Plutzky, MD, and Michael Farkouh, MD, speak with University of Maryland's Matthew Weir, MD, about the growing involvement of renal care in modern heart disease patients.

In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.

New cohort analysis suggest updates to broaden the age and smoking-rate eligibility may have benefitted the historic disparity in low-dose CT screening practice.

A cross-sectional analysis of a Penn Medicine primary care practice shows which patients may prefer a phone or tablet versus a computer.

Rebecca T. Brown, MD, MPH, discusses the growing prevalence of older homeless adults, and what diseases community leaders and caregivers are combating most frequently in them.

New comparative effectiveness data go against CDC recommendations for tapering or abruptly ending long-term opioid prescription.

The newest indications for the novel oral antiviral drug will make it available as an acute treatment and prophylaxis for children this flu season.

The agency has taken new action against Juul while experts worry about youth addiction and health impacts. But the e-cigarette market has been already well established in the US.

New phase 3 ENHANCE-2 data support a potential submission by Verona Pharma to the FDA.

Reena Mehra, MD, MS, reviews telling signs, the role of obesity, and the importance of proper testing for sleep apnea.

The pivotal DERMIS trial author discusses extended assessment and prescribing strategies for the latest psoriasis agent.

A retrospective analysis suggests there are significant disparities in dermatologist visit duration based on patient race and ethnicity.

Dermatologist Raj Chovatiya, MD, PhD, discusses practical use of the newest topical therapy approved by the FDA.

The Cleveland Clinic Director of Sleep Disorders Research navigates the complexities of OSA presentation, progression, management and eradication with the Lungcast team.

The indication to Arcutis makes the once-daily topical cream the first marketed PDE4 inhibitor of its kind.

An analysis of survey responses show tolerance toward public health official harassment and threatening has worsened since 2020.

A cohort analysis of Rhode Island data showed populations at high risk of SARS-CoV-2 exposure are at greater likelihood of reinfection, and would benefit even more greatly from vaccination.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

Jennifer Green, MD, discusses the benefit of relatively new innovations including continuous glucose monitoring and smart insulin pens.